Compare UCTT & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | SANA |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.4B |
| IPO Year | 2004 | 2021 |
| Metric | UCTT | SANA |
|---|---|---|
| Price | $43.72 | $4.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $32.50 | $7.83 |
| AVG Volume (30 Days) | 820.5K | ★ 3.0M |
| Earning Date | 02-23-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,110,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.65 | N/A |
| 52 Week Low | $16.66 | $1.26 |
| 52 Week High | $46.00 | $6.55 |
| Indicator | UCTT | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 86.95 | 51.88 |
| Support Level | $31.17 | $4.37 |
| Resistance Level | $46.00 | $4.92 |
| Average True Range (ATR) | 1.99 | 0.29 |
| MACD | 1.60 | 0.02 |
| Stochastic Oscillator | 89.57 | 64.14 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.